# Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial.

> **NCT03174405** · PHASE2 · COMPLETED · sponsor: **AIO-Studien-gGmbH** · enrollment: 43 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03174405
- **Lead sponsor:** AIO-Studien-gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-17
- **Primary completion:** 2020-07-16
- **Final completion:** 2021-07-16
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2022-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03174405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03174405, "Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03174405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*